Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5192061 | 0.89 | GPR119 (0.51) | KDM4EPKMGPR119HPGD | |
| SCHEMBL8423975 | 0.88 | GPR119 (0.50) | KDM4EPKMGPR119HPGD | |
| Benzene SCHEMBL3360754 | 0.87 | KDM4E (0.54) | KDM4EPKMGPR119 | |
| SCHEMBL6156324 | 0.87 | HPGD (0.58) | KDM4EPKMGPR119HPGD | |
| SCHEMBL4096002 | 0.87 | GPR119 (0.50) | KDM4EPKMGPR119HPGD | |
| SCHEMBL5190671 | 0.86 | KDM4E (0.52) | KDM4EPKMGPR119HPGD | |
| SCHEMBL6150245 | 0.85 | GPR119 (0.51) | KDM4EPKMGPR119HPGD | |
| SCHEMBL6156540 | 0.85 | GPR119 (0.53) | KDM4EPKMGPR119HPGD | |
| SCHEMBL21524557 | 0.84 | GPR119 (0.52) | KDM4EPKMGPR119HPGD | |
| SCHEMBL792031 | 0.84 | KDM4E (0.53) | KDM4EPKMGPR119HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507760-B1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA AS (DK) | 2007-08-01 | — | — | EP | claimed |
| US-20050215588-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2005-09-29 | — | — | US | claimed |
| CN-1662501-A | Cyanoguanidine prodrugs | LEO PHARMA AS (DK) | 2005-08-31 | — | — | CN | claimed |
| EP-1507760-A1 | CYANOGUANIDINE PRODRUGS | Leo Pharma A/S (DK) | 2005-02-23 | — | — | EP | claimed |
| WO-2003097601-A1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA A/S (DK) | 2003-11-27 | — | — | WO | claimed |
| CN-100503570-C | Cyanoguanidine prodrugs | LEO PHARMA AS (DK) | 2009-06-24 | — | — | CN | disclosed |
| US-20070249676-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2007-10-25 | — | — | US | disclosed |
| US-7253193-B2 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2007-08-07 | — | — | US | disclosed |
| EP-1507760-B1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA AS (DK) | 2007-08-01 | — | — | EP | disclosed |
| US-20050215588-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2005-09-29 | — | — | US | disclosed |
| CN-1662501-A | Cyanoguanidine prodrugs | LEO PHARMA AS (DK) | 2005-08-31 | — | — | CN | disclosed |
| EP-1507760-A1 | CYANOGUANIDINE PRODRUGS | Leo Pharma A/S (DK) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003097601-A1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA A/S (DK) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249676-A1 | Cyanoguanidine prodrugs | CCNT1, CCND2, CCNT2 | KDM4E 2664/4885PKM 1258/4885GPR119 497/4885 |
| US-20050215588-A1 | Cyanoguanidine prodrugs | CCNT1, CCND2, CCNT2 | KDM4E 2664/4885PKM 1258/4885GPR119 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.